arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Aktis Oncology, Inc.

AKTS Health Care Biotechnology: Pharmaceutical Preparations
$15.73
▼ -4.2% Today
as of Oct 23, 16:45 ET
Last 30 days -32.11% Sep 14 → Oct 23
$14.41 $16.76 $19.12 $21.47 $23.82 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$16.50
High
$16.61
Low
$15.65
Volume
$241,572
Avg Vol
$368,321
Mkt Cap
$1.3B
P/E (TTM)
—
Beta
—
52w High
$34.19
52w Low
$14.72
Div Yield
—
Shares Out
$53M

Recent Press Releases & News last 60 days · 2 items

Oct 1 · 12:00 PR GlobeNewswire
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Sep 9 · 12:00 PR GlobeNewswire
Aktis Oncology to Present at Upcoming September Investor Conferences

AKTS earnings at a glance

The options market is pricing a move of about ±8.4% after the report, a range of roughly $14.41 to $17.05 from today's $15.73. Over its last 1 reports the stock rose the next day 0 times and fell 1, moving ±1.8% on average; after the most recent report on May 11, 2026 it moved -1.8%. That means options currently expect more movement than AKTS has typically delivered. AKTS beat the consensus EPS estimate in 0 of its last 1 reported quarters. Implied volatility is currently 54%. The share price of $15.73 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$15
$34
5% of range
Avg surprise (last 1)
-22.6%
Avg reaction (last 1)
-1.8%
0% positive
Latest IV / EM
54%
EM ±8.4% · $18 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-22.39$-16.87$-11.35$-5.83$-0.31 Actual $-18.60Actual $-22.39Actual $-0.38Est $-0.31Actual $-0.44 MarJunMar/2026Jun
Revenue vs Net Income Revenue Net income
$-24M$-17M$-10M$-3M$4M Mar 25Jun 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.44 — — — — financials
Mon May 11, 2026Mar/2026 $-0.38 $-0.31 -22.6% — -1.8% earnings
Mon Jun 30, 2025Jun 2025 $-22.39 — — — — financials
Mon Mar 31, 2025Mar 2025 $-18.60 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Revenue$3M$3M—$2M$1M
Cost of revenue—————
Gross profit—————
Operating income$-29M$-23M—$-21M$-18M
Net income$-24M$-18M—$-18M$-15M
EPS (diluted)$-0.44$-0.38—$-22.39$-18.60

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Cash & equivalents$82M$372M$38M$110M$58M
Inventory—————
Total current assets$525M$544M$230M——
Total assets$558M$577M$265M——
Long-term debt—————
Total liabilities$73M$71M$78M——
Total equity$485M$506M$-146M$-118M$-102M

Implied volatility — last 90 days

53%100%147%195%242% Jul 15 — IV 157% · EM ±40.0%Jul 16 — IV 124% · EM ±31.2%Jul 17 — IV 125% · EM ±30.9%Jul 20 — IV 139% · EM ±32.8%Jul 21 — IV 141% · EM ±32.9%Jul 22 — IV 132% · EM ±30.1%Jul 23 — IV 138% · EM ±31.0%Jul 24 — IV 142% · EM ±31.4%Jul 27 — IV 136% · EM ±28.4%Jul 28 — IV 119% · EM ±24.4%Jul 29 — IV 133% · EM ±26.6%Jul 30 — IV 102% · EM ±20.0%Jul 31 — IV 135% · EM ±25.8%Aug 03 — IV 157% · EM ±27.8%Aug 04 — IV 133% · EM ±23.0%Aug 05 — IV 147% · EM ±24.5%Aug 06 — IV 142% · EM ±23.0%Aug 07 — IV 147% · EM ±23.0%Aug 14 — IV 139% · EM ±15.3%Aug 17 — IV 242% · EM ±20.2%Aug 19 — IV 105% · EM ±6.2%Aug 20 — IV 148% · EM ±6.2%Aug 24 — IV 111% · EM ±23.1%Aug 25 — IV 130% · EM ±26.6%Aug 26 — IV 134% · EM ±26.8%Aug 27 — IV 93% · EM ±18.3%Aug 28 — IV 95% · EM ±18.2%Aug 31 — IV 118% · EM ±20.8%Sep 01 — IV 93% · EM ±16.0%Sep 02 — IV 140% · EM ±23.4%Sep 03 — IV 132% · EM ±21.4%Sep 04 — IV 127% · EM ±19.8%Sep 07 — IV 143% · EM ±19.8%Sep 08 — IV 166% · EM ±22.0%Sep 09 — IV 166% · EM ±20.8%Sep 11 — IV 126% · EM ±13.9%Sep 14 — IV 78% · EM ±6.5%Sep 21 — IV 104% · EM ±21.8%Sep 22 — IV 123% · EM ±25.1%Sep 23 — IV 150% · EM ±30.0%Sep 24 — IV 134% · EM ±26.2%Sep 25 — IV 134% · EM ±25.7%Sep 28 — IV 112% · EM ±19.9%Sep 29 — IV 146% · EM ±25.1%Oct 01 — IV 184% · EM ±29.7%Oct 02 — IV 54% · EM ±8.4%

Sector peers

ORIC
Oric Pharmaceuticals, Inc.
$1.3B $13.17-4.9%
TYRA
Tyra Biosciences, Inc.
$1.4B $20.45-0.7%
DMRA
Damora Therapeutics, Inc.
$1.2B $21.09-2.0%
AVBP
ArriVent BioPharma, Inc.
$1.4B $21.00+9.8%
GHRS
GH Research PLC
$1.4B $18.07-4.4%
RARE
Ultragenyx Pharmaceutical Inc.
$1.5B $15.65-1.7%

AKTS earnings FAQ

What is AKTS's expected move for earnings?

Options currently price a move of about ±8.4%, or $1.32 per share either way from $15.73.

How does AKTS stock usually react to earnings?

Across the last 1 reports the average next-day move was ±1.8%, up 0 times and down 1 times.

What is AKTS's implied volatility?

AKTS's at-the-money implied volatility is about 54% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in